These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 18640930)
1. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930 [TBL] [Abstract][Full Text] [Related]
2. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. You DD; Lee HG; Heo JS; Choi SH; Choi DW J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638 [TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477 [TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Chen J; Li D; Killary AM; Sen S; Amos CI; Evans DB; Abbruzzese JL; Frazier ML Ann Surg Oncol; 2009 Feb; 16(2):431-9. PubMed ID: 19020940 [TBL] [Abstract][Full Text] [Related]
9. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G; J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518 [TBL] [Abstract][Full Text] [Related]
10. Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. Evans DB J Gastrointest Surg; 2001; 5(1):2-5. PubMed ID: 11370617 [No Abstract] [Full Text] [Related]
11. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G; Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809 [TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S; Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735 [TBL] [Abstract][Full Text] [Related]
13. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019 [TBL] [Abstract][Full Text] [Related]
14. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923 [TBL] [Abstract][Full Text] [Related]
16. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005 [TBL] [Abstract][Full Text] [Related]
19. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. Mehta VK; Fisher G; Ford JA; Poen JC; Vierra MA; Oberhelman H; Niederhuber J; Bastidas JA J Gastrointest Surg; 2001; 5(1):27-35. PubMed ID: 11309645 [TBL] [Abstract][Full Text] [Related]
20. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Katz MH; Wang H; Balachandran A; Bhosale P; Crane CH; Wang X; Pisters PW; Lee JE; Vauthey JN; Abdalla EK; Wolff R; Abbruzzese J; Varadhachary G; Chopin-Laly X; Charnsangavej C; Fleming JB J Gastrointest Surg; 2012 Jan; 16(1):68-78; discussion 78-9. PubMed ID: 22065318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]